

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Jeffrey A. Engelman¹ and Pasi A. Jänne^{2,3}

Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non-small cell lung cancer patients whose tumors harbor somatic mutations in *EGFR*. All patients, however, ultimately develop resistance to these agents. Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers. Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in *EGFR*, *EGFR* T90M, and amplification of the *MET* oncogene. These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies. Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients.

Background

Epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non-small cell lung cancer (NSCLC) treatment (1, 2, 3). Both agents were found to have evidence of antitumor activity in phase II clinical trials but only erlotinib was associated with a survival benefit in a phase III clinical trial (4, 5). Although the benefits of erlotinib were statistically significant, they were clinically modest (median survival of 6.7 months versus 4.7 months for erlotinib and placebo, respectively; $P < 0.0001$) and have prompted studies to identify those patients most likely to benefit from erlotinib therapy. In clinical studies, gefitinib and erlotinib are most effective in never-smokers with NSCLC (4, 5).

Subsequent molecular studies identified somatic mutations in *EGFR* as a major determinant underlying the dramatic clinical responses following treatment with gefitinib (6, 7) and erlotinib (8). Somatic mutations in *EGFR* are found in 10% to 15% of Caucasian and in 30% to 40% of Asian NSCLC patients. *EGFR* mutations are present more frequently in never-smokers,

females, those with adenocarcinoma, and in patients of East Asian ethnicity (9). These are the same groups of patients previously clinically identified as most likely to benefit from gefitinib or erlotinib (1, 2, 4). *EGFR* mutations associated with increased response to gefitinib and erlotinib are found in the first four exons (exons 18-21) of the tyrosine kinase domain of EGFR. The mutations reported thus far have been predominantly of two types: 45% are deletions involving at least 12 nucleotides in exon 19, eliminating a conserved LREA motif, and 40% are single point mutations in exon 21 (L858R). The exon 19 deletions and L858R are the most common *EGFR* mutations and are also the ones that have been most extensively evaluated to date and closely linked to the sensitivity of gefitinib and erlotinib (reviewed in ref. 10).

Six prospective clinical trials treating chemotherapy naïve patients with *EGFR* mutations with gefitinib or erlotinib have been reported to date (11-16). Cumulatively, these studies have prospectively identified and treated more than 200 patients with *EGFR* mutations. Together, they show radiographic response rates ranging from 55% to 82% and median times to progression of 9.4 to 13.3 months in the patients treated with gefitinib and erlotinib. These outcomes are 3- to 4-fold greater than historically observed with platin-based chemotherapy (20% to 30% and 3-4 months, respectively) for advanced NSCLC (17). Despite the dramatic efficacy of erlotinib and gefitinib in NSCLC patients with *EGFR* mutations, however, all patients will ultimately develop resistance (i.e., acquired resistance) to these agents. It is critical to understand the mechanisms of acquired resistance because it may lead to the development of effective therapies for patients who clinically develop acquired resistance to gefitinib or erlotinib.

Clinical studies have also shown that a small population of patients with amplified, wild-type *EGFR* lung cancers also benefit from gefitinib or erlotinib (18, 19). In addition, a significant portion of NSCLC patients develops stable disease after treatment with EGFR inhibitors (20). The mechanism(s)

Authors' Affiliations: ¹Massachusetts General Hospital Cancer Center; ²Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute; and ³Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Received 12/4/07; revised 1/11/08; accepted 1/11/08.

Grant support: NIH grant 1R01CA114465-01 and Hazel and Sam Bellin Research Fund for Thoracic Oncology (P.A. Jänne), National Cancer Institute K08CA120060-01 (J.A. Engelman), and American Cancer Society RSG-06-102-01-CCE (P.A. Jänne and J.A. Engelman).

Requests for reprints: Pasi A. Jänne, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, D820A, 44 Binney Street, Boston, MA 02115. Phone: 617-632-6036; Fax: 617-582-7683; E-mail: pjanne@partners.org.

© 2008 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-07-2248

of underlying sensitivity to gefitinib or erlotinib, however, are not well characterized in this patient population. Acquired resistance mechanisms have been studied most extensively in *EGFR* mutant cancers and will be the subject of this review. It remains to be determined if these resistance mechanisms are shared with wild-type *EGFR* cancers.

***EGFR* Mutant Tumors Are Addicted to *EGFR* Signaling**

To understand how *EGFR* mutant NSCLCs can develop resistance to *EGFR* TKIs, it is first critical to understand the normal signaling mechanisms in these tumors. *EGFR* mutant tumors are dependent or “addicted” to *EGFR* signaling for their growth and survival (21–23). Studies to date suggest that, in these cancers, several (if not all) of the critical downstream signaling pathways, including the phosphoinositide 3-kinase (PI3K)/Akt, signal transducers and activators of transcription, and extracellular signal-regulated kinase 1 and 2 pathways, are solely controlled by *EGFR*. Thus, when the tumors are exposed to *EGFR* inhibitors, these intracellular pathways are turned off and the cancer cells undergo apoptosis (21, 22, 24, 25). In contrast, *EGFR* does not singularly regulate these pathways in most other lung cancers, and these cancers are impervious to *EGFR* inhibitors.

The detailed molecular events that lead to activation of these downstream signaling events are just beginning to be understood. This understanding facilitates the discovery of potential resistance mechanisms because cancers adopt novel ways of activating these pathways to circumvent the effects of *EGFR* inhibition (see below). *EGFR* is one of a family of four *erbB* family members. Two other family members, *HER2* and *erbB3*, are highly implicated in promoting *EGFR* activation of downstream signaling. *ErbB3* is a unique member of this family in that it is believed to be “kinase dead” (Fig. 1A). On heterodimerization with other *erbB* family members, however, *ErbB3* is phosphorylated on tyrosines and serves as a scaffold to activate downstream signaling. In lung cancers that are sensitive to *EGFR* inhibitors, PI3K/Akt is activated by binding to phosphorylated *erbB3* (26). In contrast, cancers that are not sensitive to *EGFR* inhibitors primarily use non-*erbB3* mechanisms for activating PI3K (26). There are now several studies reporting a correlation between gefitinib sensitivity and *erbB3* expression in NSCLC cell lines (25–27). In fact, *erbB3* expression analysis identified patients that most benefited from *EGFR* inhibitors (28).

HER2 (*erbB2*) also seems to play a prominent role in *EGFR* mutant cancers. *HER2* amplification, as determined by fluorescence *in situ* hybridization analysis, was identified as a positive predictor of response to *EGFR* TKIs (29). In a small study, the most powerful predictor of response was the presence of both *HER2* amplification and an *EGFR* mutation (29). *HER2* expression may increase *EGFR* recycling to the membrane and prevent its degradation. Furthermore, *HER2* may increase signaling to *erbB3* in an *EGFR*-dependent manner via lateral signaling (30).

It is also clear that *EGFR* activity regulates extracellular signal-regulated kinase 1 and 2 signaling pathways as well in TKI-sensitive cancers. The detailed molecular mechanisms leading from *EGFR* kinase to extracellular signal-regulated kinase 1 and 2 activation, however, remain to be elucidated. Similarly, signal transducer and activator of transcription 3 seems to be active in

EGFR mutant cancers. Although a study found that *EGFR* kinase activity was not necessary for signal transducer and activator of transcription 3 tyrosine phosphorylation, it reported that *EGFR* kinase activity was necessary for its serine phosphorylation, a process often required for its full activation (31). In *EGFR* mutant cancers, it is clear that inhibition of *EGFR* turns off these downstream signaling events and, to become resistant, these cancers seem to find ways to maintain their activity.

Secondary *EGFR* Mutations

Two main mechanisms of acquired resistance have been identified. The first is a secondary *EGFR* mutation, T790M, that renders gefitinib and erlotinib ineffective inhibitors of *EGFR* kinase activity (Fig. 1B; refs. 32, 33). *EGFR* T790M has been detected both from tumors of *EGFR* mutant NSCLC patients who have developed clinical resistance to gefitinib or erlotinib and from *in vitro* gefitinib-resistant *EGFR* mutant cell lines (32–37). To date, the *EGFR* T790M mutation is found in ~50% of tumors (24 of 48) from patients that have developed acquired resistance to gefitinib or erlotinib (34–36). In one patient, another secondary *EGFR* mutation, D761Y, has also been reported (35).

The *EGFR* T790M mutation occurs in an analogous position to known resistance mutations to imatinib in other kinases (T315I in *ABL*, T674I in *PDGFRA*, and T670I in *KIT*; refs. 38–40). The conserved threonine residue among these different kinases, located near the kinase active site, is often referred to as the gatekeeper mutation. The exact mechanism through which T790M causes gefitinib/erlotinib resistance is not completely understood. In *ABL*, the T315I mutation causes a steric hindrance and causes imatinib binding (38, 41). Whether this same mechanism also occurs in *EGFR* T790M remains to be determined.

Cancers that become resistant to kinase inhibitors through a secondary mutation are still likely to be dependent on the activated kinase for their growth and survival. Thus, alternative strategies of inhibiting *EGFR* T790M may be therapeutically efficacious. This has prompted the preclinical and clinical development of second-generation kinase inhibitors (41). For *EGFR*, second-generation irreversible *EGFR* inhibitors have shown activity in gefitinib-resistant preclinical models of NSCLC containing *EGFR* T790M (42, 43). Irreversible inhibitors, including HKI-272 and PF00299804, are able to inhibit *EGFR* phosphorylation and lead to growth inhibition of NSCLC or Ba/F3 cell lines containing *EGFR* T790M (42, 43). These agents are also ATP mimetics similar to gefitinib and erlotinib but, unlike gefitinib or erlotinib, they covalently bind Cys-797 of *EGFR*. How the irreversible nature of these agents allows them to inhibit *EGFR* phosphorylation is unclear. It is possible that by covalently binding to *EGFR*, the local concentration of these agents increases substantially (compared with gefitinib or erlotinib, which is a reversible inhibitor), thus providing a means of inhibiting *EGFR* phosphorylation despite the presence of a T790M mutation.


Alternative Mechanisms for Activating Downstream Signaling

As mentioned previously, if an *EGFR* mutant cancer can maintain activity of downstream signaling pathways in the

presence of gefitinib or erlotinib, this may lead to resistance. Indeed, several preclinical studies have shown that continued activation of downstream signaling, especially the PI3K pathway, is sufficient to confer resistance to EGFR TKIs. Most, if not all, laboratory models of acquired resistance show

continued activation of the PI3K pathway despite TKI treatment (36, 37, 44, 45). Additionally, activation of PI3K/Akt signaling by an ectopically expressed p110 α -activating mutant (*PIK3CA*) confers an EGFR mutant cancer resistant to TKIs (44). Similarly, in *HER2*-amplified breast cancers, the presence of an activating

Fig. 1. EGFR signaling in gefitinib/erlotinib-sensitive and gefitinib/erlotinib-resistant *EGFR* mutant NSCLCs. **A.** EGFR phosphorylates erbB3 to activate PI3K/Akt signaling in gefitinib/erlotinib-sensitive NSCLCs. In such cancers, following gefitinib/erlotinib treatment, EGFR, erbB3, and Akt phosphorylations are turned off. **B.** gefitinib/erlotinib are unable to inhibit EGFR phosphorylation in the presence of *EGFR* T790M. EGFR signaling persists in the presence of gefitinib/erlotinib, leading to persistent erbB3 and Akt phosphorylation. **C.** MET can also activate PI3K/Akt signaling through erbB3. In NSCLCs with *MET* amplification, gefitinib/erlotinib can still inhibit EGFR phosphorylation but not erbB3 phosphorylation. This leads to persistent activation of PI3K/Akt signaling via erbB3 in an EGFR-independent manner. **D.** other potential mechanisms of gefitinib/erlotinib resistance. These potential mechanisms include alternative ways of maintaining PI3K/Akt signaling, such as by an oncogenic *PIK3CA* or by other receptor tyrosine kinases that could activate PI3K/Akt signaling in an erbB3-independent fashion. In such cancers, gefitinib/erlotinib would be expected to inhibit EGFR and erbB3 phosphorylation but not Akt phosphorylation. Adapted by permission from Macmillan Publishers Ltd. (Artega CL. *HER3* and mutant *EGFR* meet *MET*. *Nat Med* 2007;13:675–7), copyright 2007.



p110 α mutation or PTEN loss predicts a lack of response to trastuzumab (46). Although loss of PTEN or acquisition of a *PIK3CA* mutation has not been identified as a mechanism of resistance in lung cancer specimens, these analogous findings and preclinical studies suggest that if a cancer can find a way to effectively activate PI3K independent of EGFR activity, it will become resistant to EGFR TKIs.

Recently, amplification of *MET*, a receptor tyrosine kinase, was identified as another acquired resistance mechanism (36). This was originally identified in the HCC827 cells (*EGFR* exon 19 mutation and amplified) that had been made resistant to gefitinib *in vitro*. Interestingly, *MET* causes resistance because it activates erbB3-dependent activation of PI3K (Fig. 1C). Furthermore, it was determined that *MET* signals through erbB3 in most *MET*-amplified cancers (36). This redundant activation of erbB3 permits the cells to transmit the same downstream signaling in the presence of EGFR inhibitors. Thus, concomitant inhibition of both EGFR and *MET* is required to kill the resistant cells. In the initial study, 22% (4 of 18) of NSCLCs with acquired resistance to gefitinib/erlotinib had *MET* amplification in the resistant specimens. It is interesting to speculate that *MET* amplification is a prevalent resistance mechanism because it activates PI3K signaling in the same way as EGFR, via erbB3.

EGFR T790M and *MET* amplification account for ~60% to 70% of all known causes of acquired resistance to gefitinib or erlotinib. Thus, other mechanisms of acquired resistance are likely to be discovered. Based on the preclinical models to date, such mechanisms are likely to lead to maintenance of PI3K/Akt signaling in the presence of gefitinib/erlotinib. This could occur through erbB3 (such as for *EGFR* T790M or *MET* amplification) or by an erbB3-independent mechanism (Fig. 1D). It will be important to continue to study preclinical models and tumors from NSCLC patients that have developed gefitinib/erlotinib resistance to uncover novel resistance mechanisms.

Clinical Translation Advances

Several clinical trials are under way, aimed at inhibiting known resistance mechanisms in NSCLC patients that have clinically developed acquired resistance to gefitinib or erlotinib. Ongoing trials are evaluating irreversible EGFR inhibitors, the combination of EGFR and *MET* kinase inhibitors, or Hsp90 inhibitors as strategies to overcome acquired resistance in NSCLC patients (36, 42, 43, 47, 48). There are several challenges in translating the preclinical studies into effective clinical therapies, however. The first challenge is accurately identifying which patients have which mechanism of resistance. The vast majority of NSCLC patients who develop acquired

resistance to gefitinib or erlotinib do not undergo repeated tumor biopsies at the time when their cancer develops resistance. This is critical in that the therapeutic strategy aimed at overcoming resistance may not be effective in all resistant patients. For example, irreversible EGFR inhibitors are not effective in preclinical models of gefitinib resistance that are mediated by *MET* amplification (43). A second challenge is that, unlike in preclinical models that focus on single mechanisms of resistance, multiple mechanisms of resistance can occur concurrently in the same patient. Both *MET* amplification and *EGFR* T790M have been detected in the same resistant tumor specimen (36, 49). In addition, they have been found to occur independently in different metastatic sites in the same patient (36). Thus, a therapeutic strategy aimed solely at inhibiting *EGFR* T790M or *MET* amplification may not be very effective or may lead only to regression of a subset of metastases that contains the particular mechanism of resistance. A more comprehensive and potentially effective strategy may be a combination of an irreversible EGFR and a *MET* kinase inhibitor. At present, there are no ongoing clinical trials combining these classes of agents. Alternatively, strategies such as Hsp90 inhibitors may also be effective as both EGFR and *MET* are known Hsp90 client proteins (47, 50). A third challenge relates to the biological definition and detection of resistance mechanisms. As most *EGFR* mutant NSCLCs also contain a concurrent copy gain at the *EGFR* locus, the *EGFR* T790M mutation can sometimes be present as a minor allele and yet be sufficient to cause drug resistance (18, 44). In such cases, *EGFR* T790M may go undetected by conventional sequencing techniques and more sensitive mutation detection methods are necessary for accurate identification of *EGFR* T790M (44). Similarly, there are challenges with the detection of *MET* amplification. The definition of what constitutes clinically significant *MET* amplification (i.e., that causes gefitinib/erlotinib resistance) is also not currently well defined. This too will be important in deciding on which patients should be treated with *MET* kinase inhibitors for their gefitinib/erlotinib-resistant NSCLC.

Gefitinib and erlotinib are effective therapies for patients with *EGFR* mutant NSCLC (11–16). It will continue to be important to identify and study the mechanisms of resistance that develop to these agents as a means of rationally designing the next-generation clinical studies.

Disclosure of Potential Conflicts of Interest

P.A. Jänne has received commercial research support from Pfizer, has consulted with AstraZeneca, Roche and Boehringer Ingelheim, and received royalties from Genzyme and is part of a pending patent application on EGFR mutations. J. A. Engleman has consulted with Roche.

References

1. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;290:2149–58.
2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2003;21:2237–46.
3. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. *J Clin Oncol* 2004;22:3238–47.
4. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract 7022]. *Proc Am Soc Clin Oncol* 2004;23.
5. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 2005;366:1527–37.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497–500.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
8. Pao W, Miller V, Zakowski M, et al. EGFR receptor gene mutations are common in lung cancers from “never

- smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306–11.
9. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005;97:339–46.
 10. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. *J Clin Oncol* 2005;23:3227–34.
 11. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. *J Clin Oncol* 2006;24:3340–6.
 12. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) [abstract 7020]. *J Clin Oncol* 2006;24.
 13. Okamoto I, Kashii T, Urata Y, et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): results of West Japan Thoracic Oncology Group trial (WJTOG0403) [abstract 7073]. *J Clin Oncol* 2006;24.
 14. Sutani A, Nagai Y, Udagawa K, et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp [abstract 7076]. *J Clin Oncol* 2006;24.
 15. Morikawa N, Inoue A, Suzuki T, et al. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan [abstract 7077]. *J Clin Oncol* 2006;24.
 16. Sequist LV, Martins RG, Spiegel D, et al. ITARGET: a phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. *J Clin Oncol* 2007 ASCO Annu Meet Proc 2007;25; No18s (June 20 Supplement): 7504.
 17. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 2002;346:92–8.
 18. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst* 2005;97:643–55.
 19. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. *N Engl J Med* 2005;353:133–44.
 20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353:123–32.
 21. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science* 2004;305:1163–7.
 22. Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. *Cancer Res* 2004;64:7241–4.
 23. Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heel of cancer. *Science* 2002;297:63–4.
 24. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. *J Natl Cancer Inst* 2005;97:1185–94.
 25. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. *Cancer Res* 2005;65:226–35.
 26. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. *Proc Natl Acad Sci U S A* 2005;102:3788–93.
 27. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. *Mol Cancer Ther* 2004;3:465–72.
 28. Fujimoto N, Wislez M, Zhang J, et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. *Cancer Res* 2005;65:11478–85.
 29. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol* 2005;23:5007–18.
 30. Engelman JA, Cantley LC. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. *Clin Cancer Res* 2006;12:4372–6s.
 31. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. *Cancer Res* 2006;66:3162–8.
 32. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005;352:786–92.
 33. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:1–11.
 34. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. *Clin Cancer Res* 2006;12:5764–9.
 35. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res* 2006;12:6494–501.
 36. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039–43.
 37. Ogino A, Kitao H, Hirano S, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. *Cancer Res* 2007;67:7807–14.
 38. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell* 2002;2:117–25.
 39. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. *Gastroenterology* 2004;127:294–9.
 40. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* 2003;348:1201–14.
 41. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. *Nat Rev Cancer* 2007;7:345–56.
 42. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc Natl Acad Sci U S A* 2005;102:7665–70.
 43. Engelman JA, Zejnullahu K, Gale C-M, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Res* 2008;67:11924–32.
 44. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *J Clin Invest* 2006;116:2695–706.
 45. Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. *Cancer Res* 2007;67:5779–88.
 46. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell* 2007;12:395–402.
 47. Shimamura T, Lowell AM, Engelman JA, Shapiro GL. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. *Cancer Res* 2005;65:6401–8.
 48. Regales L, Balak MN, Gong Y, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. *PLoS ONE* 2007;2:e810.
 49. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A* 2007;104:20932–7.
 50. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. *Clin Cancer Res* 2002;8:620–7.

Clinical Cancer Research

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Jeffrey A. Engelman and Pasi A. Jänne

Clin Cancer Res 2008;14:2895-2899.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/14/10/2895>

Cited articles This article cites 44 articles, 24 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/14/10/2895.full#ref-list-1>

Citing articles This article has been cited by 84 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/14/10/2895.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/14/10/2895>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.